Laboratories are the Forgotten Stakeholder in Personalized Medicine | Diaceutics

Laboratories are the Forgotten Stakeholder in Personalized Medicine

January 10th, 2013

Mark Reis

Mark Reis highlights the importance of the laboratory in the delivery of personalized medicine and explains how the Diaceutics network adds value by creating a halo effect for both the laboratory and the therapy.

[Note, July 2017: Labceutics is now known as Diaceutics]

Laboratories are often the forgotten partners in the delivery of personalized therapies to physicians worldwide, yet the research and quality of their service in delivering seamless test results to physicians can either enhance the value proposition of a targeted therapy or destroy it. The need for integrated highest quality laboratory networks in fragmented markets such as Europe and Asia are required to truly leverage the power of companion diagnostics. Our research shows that a well-designed superior laboratory service translates into a higher return on investment for targeted therapy teams. The research and experience Labceutics has in the marketplace clearly demonstrates that therapy teams seeking to improve the doctor-laboratory dynamic and facilitate use and interpretation of a particular targeted therapeutic should be engaging with laboratories that specialize in providing ‘gold-plated’ services to doctors. The Labceutics network provides a higher level of service to the point that it actually adds value to the treatment, creating a halo effect for both the laboratory and the therapy.

The quality and value of laboratory information depends on an array of factors, including selecting the right test at the right time for the right patient. There can be a significant difference in laboratory use among physicians investigating patients with the same diagnosis and also a significant number of tests that are ordered unnecessarily. Even if doctors believe a test is relevant, they may hesitate to requisition it if the order process is unwieldy or the form is confusing. Conversely, reports that are difficult to read or interpret, or that present ambiguous results, may deter physicians from reordering a test. Physicians may choose to order a test from a different laboratory, or not to order it at all. As guidelines do not necessarily specify the preferred testing method (kit or LDT), pathologists are typically responsible and trusted by physicians to determine the right method of testing, which can cause a level of confusion. Grouped together, these challenges conspire to negatively impact appropriate test adoption.

Labceutics allows pharmaceutical companies to communicate directly with laboratories that are working directly with the prescribing doctors. The quality and access of available testing is optimized for the specific personalized medicine drug launch and fully integrates into the drug brand. Labceutics ‘personalized medicine-ready footprint’ enables rapid market access, transparency and clinical services that result in significantly improved test turnaround times, resource savings and improved outcomes. Whether an LDT or in vitro diagnostic, Labceutics covers all the bases to ensure the highest testing quality, standards and delivery.

The full article and research can be found here: [php snippet=34 param=”id=89″].

 

Blogs

View all blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn